Delcure Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 15-07-2024
- Paid Up Capital ₹ 5.00 M
as on 15-07-2024
- Company Age 11 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 100.00 M
as on 15-07-2024
- Revenue -100.00%
(FY 2023)
- Profit -100.42%
(FY 2023)
- Ebitda -101.48%
(FY 2023)
- Net Worth -83.23%
(FY 2023)
- Total Assets -83.40%
(FY 2023)
About Delcure Lifesciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company has closed loans amounting to ₹10.00 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Vrinda Seth, Kanishk Jain, and Man Sharma serve as directors at the Company.
- CIN/LLPIN
U24100DL2013PLC286876
- Company No.
286876
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
31 Jan 2013
- Date of AGM
28 Apr 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
North West Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Delcure Lifesciences Limited offer?
Delcure Lifesciences Limited offers a wide range of products and services, including Sexual Wellness Products, Fertility Enhancer, Antihistamines, Levocetirizine Tablet, Pharmaceutical Tablets, Betahistine Dihydrochloride Tablet, Vitamin Tablets & Capsules, Thiamine Hydrochloride, Pharmaceutical Syrup, Oral Suspension.
Who are the key members and board of directors at Delcure Lifesciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vrinda Seth  | Director | 31-Jan-2013 | Current |
| Kanishk Jain | Director | 30-Sep-2018 | Current |
| Man Sharma | Director | 26-Oct-2022 | Current |
Financial Performance and Corporate Structure Insights of Delcure Lifesciences.
Delcure Lifesciences Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 100% decrease. The company also saw a substantial fall in profitability, with a 100.42% decrease in profit. The company's net worth observed a substantial decline by a decrease of 83.23%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Delcure Lifesciences?
In 2023, Delcure Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
14 years 2 months 
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Yes Bank Limited Creation Date: 04 Feb 2014 | ₹10.00 Cr | Satisfied |
How Many Employees Work at Delcure Lifesciences?
Delcure Lifesciences has a workforce of 419 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Delcure Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Delcure Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
